Carregant...
Cardioprotective Properties of Omecamtiv Mecarbil against Ischemia and Reperfusion Injury
Omecamtiv mecarbil (OM) is a first-in-class myosin activator. It was developed as a new inotropic therapy option for heart failure and is currently the object of a phase 3 clinical trial program. OM activates ryanodine receptors, which were shown to be involved in cardioprotection induced by conditi...
Guardat en:
| Publicat a: | J Clin Med |
|---|---|
| Autors principals: | , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
MDPI
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6463149/ https://ncbi.nlm.nih.gov/pubmed/30889854 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm8030375 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|